Checkpoint Capital L.P.
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Checkpoint Capital L.P. reported 6 stock positions worth $389.8 million. Its top holding was Rhythm Pharmaceuticals (RYTM) at 33.8% of the portfolio, followed by Argenx SE - ADR (ARGX, 31.3%) and Revolution Medicines (RVMD, 19.7%). Compared with Q1 2026, it sold out of 2, added to 3 and reduced 3. The biggest buy was Revolution Medicines (RVMD, shares +56%) and the biggest sale Argenx SE - ADR (ARGX, shares −14%).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001977548
- Portfolio Value
- $389.8M (Q2 2026)
- SEC Filing
- 0001977548-26-000005 ↗ filed Aug 14, 2026
Holdings Value
Holdings 6 stocks · $389.8M
| RYTM Rhythm Pharmaceuticals Inc. | 33.79% | 1,186,000 | $131.7M | Reduce -3.4% |
| ARGX Argenx SE - ADR | 31.25% | 131,283 | $121.8M | Reduce -14.2% |
| RVMD Revolution Medicines Inc. | 19.72% | 410,353 | $76.9M | Add +56.3% |
| CYTK Cytokinetics Inc. | 10.38% | 475,000 | $40.5M | Add +163.9% |
| IRON Disc Medicine Inc. | 4.51% | 240,125 | $17.6M | Reduce -16.2% |
| TRVI Trevi Therapeutics Inc. | 0.36% | 75,000 | $1.4M | Add +50.0% |
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $389.8M | RYTM, ARGX, RVMD, CYTK, IRON |
| Q1 2026 | 8 | $278.7M | ARGX, RYTM, RVMD, IRON, CYTK |
| Q4 2025 | 6 | $315.6M | ARGX, RYTM, IRON, RVMD, CORT |
| Q3 2025 | 10 | $298.5M | ARGX, RYTM, CORT, IRON, RVMD |
| Q2 2025 | 8 | $214.6M | ARGX, RYTM, CORT, IRON, RVMD |
| Q1 2025 | 14 | $182.3M | ARGX, RYTM, RVMD, SLNO, IRON |
| Q4 2024 | 16 | $196.5M | ARGX, RYTM, PHAT, AXSM, IRON |
| Q3 2024 | 16 | $201.6M | ARGX, RYTM, PHAT, CYTK, AXSM |
| Q2 2024 | 16 | $165.9M | RYTM, ARGX, AXSM, AVDL, PTGX |
| Q1 2024 | 17 | $149.6M | RYTM, ARGX, CYTK, AVDL, AXSM |